New boost for pancreatic cancer therapy

April 2, 2012, Fox Chase Cancer Center

Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar)—the chemotherapy drug that is considered standard therapy for the disease. Although gemcitabine is the first line of defense against pancreatic cancer, many cells find ways to evade the treatment. The new research, which will be presented at the AACR Annual Meeting 2012 on Monday, April 2, found several compounds that appear to improve the cancer-killing effect of gemcitabine.

After a diagnosis of , only 5 % of people live beyond five years—so any technique that boosts the effects of the current regimen could have a major impact on survival.

"Although gemcitabine can successfully kill many pancreatic cancer , using it as a single agent hasn't really been effective because there are still a small percentage of cells that develop some kind resistance to the drug," says study author Neil Beeharry, Ph.D., a postdoctoral associate in the lab of Tim J. Yen, Ph.D., also first author on the paper, at Fox Chase Cancer Center in Philadelphia. "I think finding this 'X factor' is really going to enhance our ability to treat patients."

During the study, Beeharry, Yen and their co-authors Jeffrey R. Peterson, Ph. D. and Lauren Fink, Ph. D., searched for compounds that would boost the effects of gemcitabine by targeting those resistant cells. They started with kinase —a class of drugs that target enzymes known as kinases—which play an important role in cancer and other cellular processes. As a result, kinase inhibitors are increasingly being used to treat various types of cancer.

They first exposed a pancreatic cell line to gemcitabine, then to 160 kinase inhibitors. Most of the kinase inhibitors either didn't do anything or killed cells that hadn't been exposed to gemcitabine and therefore had no resistance to it, suggesting they might be harmful to normal cells. However, a small percentage—around 5%—did not kill cells that hadn't been treated by gemcitabine, but did appear to hurt the cancer cells that were treated with gemcitabine. This suggested these compounds were specifically targeting only those cells affected by gemcitabine.

The researchers then looked up these inhibitors in a first-of-its-kind database established last year by Fox Chase scientist, Jeffrey R. Peterson, Ph.D. (also co-author on the paper) and colleagues, which catalogued the effects of nearly 200 kinase inhibitors. By using this database, they learned the cellular pathways targeted by these specific inhibitors— information which may one day help doctors customize therapies even further, says Beeharry.

Ultimately, by boosting the effects of , a complementary kinase inhibitor may enable doctors to administer a lower dose of chemotherapy, with fewer side effects.

Ideally, researchers will develop a similar approach to improve the effects of other chemotherapy drugs for particularly deadly cancers, such as platinum-based treatments for ovarian cancer, Yen explains. "The field is moving towards this rationally designed approach, using standard therapy and a booster," he says.

Explore further: Combination therapy may enhance gemcitabine activity

Related Stories

Combination therapy may enhance gemcitabine activity

February 28, 2012
Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer ...

Recommended for you

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.